Centre for Infectious Disease Research, Diagnostics and Screening, Division Virology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; The European Programme for Public Health Microbiology Training (EUPHEM), European Center for Disease Control, Stockholm, Sweden.
Centre for Infectious Disease Research, Diagnostics and Screening, Division Virology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.
J Clin Virol. 2014 Jan;59(1):4-11. doi: 10.1016/j.jcv.2013.10.030. Epub 2013 Nov 7.
Since the emergence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012, many questions remain on modes of transmission and sources of virus. In outbreak situations, especially with emerging organisms causing severe human disease, it is important to understand the full spectrum of disease, and shedding kinetics in relation to infectivity and the ability to transmit the microorganism. Laboratory response capacity during the early stages of an outbreak focuses on development of virological and immunological methods for patient diagnosis, for contact tracing, and for epidemiological studies into sources, modes of transmission, identification of risk groups, and animal reservoirs. However, optimal use of this core public health laboratory capacity requires a fundamental understanding of kinetics of viral shedding and antibody response, of assay validation and of interpretation of test outcomes. We reviewed available data from MERS-CoV case reports, and compared this with data on kinetics of shedding and immune response from published literature on other human coronaviruses (hCoVs). We identify and discuss important data gaps, and biases that limit the laboratory preparedness to this novel disease. Public health management will benefit from standardised reporting of methods used, details of test outcomes by sample type, sampling date, in relation to symptoms and risk factors, along with the currently reported demographic, clinical and epidemiological findings.
自 2012 年中东呼吸综合征冠状病毒(MERS-CoV)出现以来,关于传播方式和病毒来源仍存在许多问题。在暴发情况下,特别是在出现引起严重人类疾病的新兴生物体时,了解疾病的全貌以及与传染性和传播微生物能力相关的病毒脱落动力学非常重要。暴发早期的实验室应对能力侧重于开发用于患者诊断、接触者追踪以及对来源、传播方式、确定风险群体和动物宿主进行流行病学研究的病毒学和免疫学方法。然而,要优化利用这种核心公共卫生实验室能力,就需要从根本上了解病毒脱落和抗体反应的动力学、检测方法的验证以及对检测结果的解释。我们审查了来自 MERS-CoV 病例报告的现有数据,并将其与其他人类冠状病毒(hCoV)发表文献中关于病毒脱落和免疫反应动力学的数据进行了比较。我们确定并讨论了重要的数据差距和偏见,这些差距和偏见限制了对这种新型疾病的实验室准备。公共卫生管理将受益于对所使用方法的标准化报告、按样本类型、采样日期报告检测结果的详细信息,以及与症状和危险因素相关的信息,以及目前报告的人口统计学、临床和流行病学发现。